Supera-CBD is a synthetic, preclinical cannabidiol derivative that targets CB2 receptors.
Supera-CBD is non-toxic and approximately 7-8X more effective than plant-derived CBD in reducing MAO-A and MAO-B, which play a role in substance addiction, in a dose-dependent manner.
Supera-CBD is being developed to address anxiety, chronic pain, and seizures and is expected to begin human trials as a therapy for epilepsy, followed by chronic pain.
Supera-CBD binds to and inhibits opioid receptors, comparing it side by side with plant-based CBD. Opioid receptors are G protein-coupled receptors, widely expressed in the brain, spinal cord, peripheral neurons, and digestive tract.
In studies with scientific collaborators, Supera-CBD has demonstrated antidepressant and anti-anxiety effects with much higher potency and efficacy than plant-derived CBD. CBD has broad therapeutic properties across a range of neuropsychiatric disorders, but without the psychoactive effects of THC.
ResearchSee the poster presented at the 3rd Annual Neuroimmunology Drug Development Conference
Download the poster presentationBuilding on CBD’s enormous pre-existing market acceptance and the FDA’s declared receptiveness to moving forward in this space, Supera-CBD is positioned to become a prescription drug alternative to unregulated CBD.
View TNF Pharmaceuticals Thought Leadership and News